Fosun Pharma (600196.SS)

Executive Summary

Fosun Pharma is a leading Chinese pharmaceutical conglomerate with a comprehensive global healthcare ecosystem spanning innovative drugs, diagnostics, vaccines, and medical devices. Valued at over $71 billion and listed on both the Shanghai and Hong Kong exchanges, the company has established itself as a key player in small molecules, biologics, and cell therapies. Its flagship antimalarial Artesun® has treated over 56 million patients, while its pipeline includes promising CAR-T therapies, monoclonal antibody biosimilars, and novel small molecules. Fosun's integrated model, combining R&D, manufacturing, and commercialization, positions it well to capture growth in China's rapidly expanding healthcare market and global opportunities. Recent developments include the completion of a Phase 1/2 trial for ORIN1001, a novel small molecule. Looking ahead, Fosun is expected to benefit from several catalysts: potential regulatory approval of its CAR-T therapy (FKC889) for certain hematological cancers in China, advancement of its biosimilar portfolio (e.g., rituximab and trastuzumab biosimilars), and partnerships or licensing deals to expand its pipeline. The company's robust financials and strategic focus on innovation underpin a positive outlook, though regulatory and competitive risks remain. We assign a conviction score of 75, reflecting solid fundamentals and near-term catalysts but tempered by China's evolving regulatory environment.

Upcoming Catalysts (preview)

• H2 2026Potential NMPA approval of CAR-T therapy FKC889 for relapsed/refractory B-cell malignancies70% success
• Q4 2026Phase 3 data readout for novel small molecule inhibitor in solid tumors60% success
• Q3 2026Launch of new biosimilar (e.g., bevacizumab or adalimumab) in China80% success